Cara Therapeutics (CARA) & WuXi PharmaTech (Cayman) (WX) Financial Review

Cara Therapeutics (NASDAQ: CARA) and WuXi PharmaTech (Cayman) (NYSE:WX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.


This table compares Cara Therapeutics and WuXi PharmaTech (Cayman)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cara Therapeutics N/A -91.47% -79.15%
WuXi PharmaTech (Cayman) 7.52% 6.93% 4.67%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cara Therapeutics and WuXi PharmaTech (Cayman), as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Therapeutics 0 2 11 0 2.85
WuXi PharmaTech (Cayman) 0 0 0 0 N/A

Cara Therapeutics currently has a consensus price target of $26.04, suggesting a potential upside of 79.80%. Given Cara Therapeutics’ higher probable upside, equities analysts plainly believe Cara Therapeutics is more favorable than WuXi PharmaTech (Cayman).

Earnings and Valuation

This table compares Cara Therapeutics and WuXi PharmaTech (Cayman)’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cara Therapeutics $90,000.00 5,246.59 -$57.28 million ($2.29) -6.32
WuXi PharmaTech (Cayman) N/A N/A N/A $1.18 38.91

WuXi PharmaTech (Cayman) has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than WuXi PharmaTech (Cayman), indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

58.9% of Cara Therapeutics shares are owned by institutional investors. 7.5% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Cara Therapeutics

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

About WuXi PharmaTech (Cayman)

WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply